Page 24 - Exscientia News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Drug candidate is being evaluated for the treatment of Alzheimer's disease psychosis - News - PharmaTimes

Second clinical molecule from Exscientia collaboration with Sumitomo Dainippon Pharma to begin Phase 1 trials in United States. Clinical study of DSP-0038, a dual targeted 5-HT1A agonist and 5-HT2A

Exscientia Announces Investment of up to $525M Proceeds to continue expansion of proprietary pipeline and end-to-end AI drug discovery capabilities $225 million Series D round closed with access up to an additional $300 million at Exscientia's discretion Financing led by SoftBank Vision Fund 2 Exscientia, a clinical stage pharmatech company using artificial intelligence (AI) to design patient-based drugs, announced that it has completed a $225 million Series D funding round. SoftBank Vision Fund 2 i led the Series D and was joined by previous round lead investors, Novo Holdings and funds mana...

Making a difference with art Updated: Updated: March 04, 2021 23:27 IST An assessment done on students of Different Arts Centre in Thiruvananthapuram brings the perks of art therapy to light Share Article Students of Different Arts Centre, with its founder Gopinath Muthukad   An assessment done on students of Different Arts Centre in Thiruvananthapuram brings the perks of art therapy to light Amal Ajayakumar is in his late teens; though basic communication is a challenge for him, Amal is a walking music library. “He has over a 100 songs stored in his brain and the way he sings, with such...

Oxford University to develop Alzheimer’s disease treatments with Exscientia 19th February 2021 The Alzheimer’s Research UK Oxford Drug Discovery Institute (ARUK-ODDI) has announced a partnership with AI drug discovery company Exscientia on the development of therapies for Alzheimer’s disease. The collaboration will focus on the NLRP3 inflammasome pathway, which has been shown to play a key role in Alzheimer’s pathogenesis. Exscientia will use its AI-driven technology to generate novel clinical assets targeting this pathway. This will build on years of research by the ARUK-ODDI, which ...